HFNC vs Two Nare HFNC in Extubated Patients

NCT ID: NCT06398951

Last Updated: 2024-05-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-07-01

Study Completion Date

2025-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

High flow nasal cannula (HFNC) are introduced to clinical practice to improve oxygenation. Our group were the first to report the use of HFNC in extubated patients that showed comparable delivery of oxygen and improved comfort. These HFNC are subsequently shown to be useful in several clinical conditions in critically ill patients including respiratory failure due to hypoxia, hypercapnia (exacerbation of chronic obstructive lung disease), or post-extubation, pre-intubation oxygenation, and others.

Recently a new mode of high flow oxygen therapy has been presented on the market where the prongs of high flow have two different diameters. These two-nare size high flow nasal cannula are capable of delivering gases at a flow rate of 15-50 L/min, similar to the conventional HFNP but the difference in the diameters provide different levels of positive pressure as compared to conventional HFNP. This positive pressure could help in gas exchange of patients who need more oxygen. These devices are approved by the Therapeutic Goods Administration (TGA); the medicine and therapeutic regulatory agency of the Australian Government.

Our aim is to compare the two size nare high flow nasal cannula with conventional high flow nasal cannula in extubated patients in intensive care unit in a randomised crossover trial. The comparison will include arterial blood gasses, physiological data including heart rate, respiratory rate, saturations as well as comfort and tolerance of the patients to two size nare high flow nasal cannuale.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomised crossover study of ventilated patients suitable for extubation was conducted. Potential patients were clinically assessed for suitability of extubation and arterial blood gasses (ABG) were performed prior to extubation to ensure the patients had optimal gas exchange. If found to be suitable for extubation, patients were extubated and were provided with a high flow blend of oxygen and air by a high flow face mask at a rate of 40 litres per minute delivering an FiO2 to ensure an oxygen saturation of 93% + 1 for 30 minutes. At the end of this 30 minute stabilization, ABG were performed and heart rate, blood pressure, and Glasgow coma score (GCS) were recorded. If the patients remained stable they were randomized to either protocol A (Duet HFNP for 30 minutes followed by conventional HFNP for 30 minutes) or protocol B ( conventional HFNP for 30 minutes followed by Duet HFNP for 30 minutes). During both protocols gas flow rate and FiO2 were maintained at exactly the same settings as used during the stabilization period. Blood gases and other physiological observations (heart rate, blood pressure, and respiratory rate, saturations, GCS, comfort score and tolerance score) were recorded at the end of each protocol. The bed side nurse assessed comfort and tolerance of patients to both the devices by a 5-point Likert scale as shown below. For the purpose of this study only medium size cannulas were used to maintain consistency. Subgroup Comparisions will be performed between those with and without nasogastric tubes and between male and female patients. Randomization is performed using sequentially numbered, sealed, opaque envelope to maintain allocation concealment.

Determine patient's comfort:

Patients provided the comfort for both duet HFNP and conventional HFNP prongs using a 5-point Likert scale;

1. No discomfort,
2. Little bit discomfort,
3. Little more discomfort,
4. Whole lot more discomfort
5. Worst discomfort.

Determine patient's tolerance:

The bedside nurse documented the patient's tolerance using a 5-point Likert scale.

0 Patient never removes the apparatus and does not complain

1. Patient complains about keeping apparatus on
2. Patient request removal of the apparatus
3. Removal of the apparatus by the patient once
4. Removal of multiple times or non-compliance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oxygen Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Two Nare (Duet) high flow nasal cannula

Recently a new mode of high flow oxygen therapy has presented on the market where the cannula of high flow have different diameters. Left cannula larger in diameter than the right. These two-nare size high flow nasal cannula are capable of delivering gases at a flow rate of 15-60 L/min, similar to the conventional HFNP but the difference in the diameters provide different levels of positive pressure as compared to conventional HFNP. The two nare nasal cannula will be used for 30 minutes to assess the gas exchange, hemodynamic parameters, the tolerance and comfort of the device to the patient.

Group Type ACTIVE_COMPARATOR

Two nare high flow nasal cannula

Intervention Type DEVICE

Recently a new mode of high flow oxygen therapy has presented on the market where the prongs of high flow have different diameters .These two-nare size high flow nasal cannula are capable of delivering gases at a flow rate of 15-50 L/min, similar to the conventional HFNP but the difference in the diameters provide different levels of positive pressure as compared to conventional HFNP.

Conventional High flow nasal cannula

Conventional high flow nasal cannula that has been used for many years will be compared with two-nare high flow nasal cannula. The two nare nasal cannula will be used for 30 minutes to assess the gas exchange, hemodynamic parameters, the tolerance and comfort of the device to the patient.

Group Type PLACEBO_COMPARATOR

Two nare high flow nasal cannula

Intervention Type DEVICE

Recently a new mode of high flow oxygen therapy has presented on the market where the prongs of high flow have different diameters .These two-nare size high flow nasal cannula are capable of delivering gases at a flow rate of 15-50 L/min, similar to the conventional HFNP but the difference in the diameters provide different levels of positive pressure as compared to conventional HFNP.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Two nare high flow nasal cannula

Recently a new mode of high flow oxygen therapy has presented on the market where the prongs of high flow have different diameters .These two-nare size high flow nasal cannula are capable of delivering gases at a flow rate of 15-50 L/min, similar to the conventional HFNP but the difference in the diameters provide different levels of positive pressure as compared to conventional HFNP.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All intubated patients imminently requiring extubation with family consent for admittance into the trial that meet the follow criteria:
* P/F ratio between \> 150 prior to extubation
* Has a functional arterial catheter to allow sample of arterial blood gasses.

Exclusion Criteria

* Patients being extubated due to withdrawal of therapy Patients being extubated, that are expected to imminently die post extubation P/F Ratio :\< 150 Patients extubated on to non-invasive ventilation Patients with known epistaxis or nasal surgery.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Peninsula Health

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

RAVINDRANATH TIRUVOIPATI, PhD

Role: PRINCIPAL_INVESTIGATOR

Peninsula Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Frankston Hospital

Frankston, Victoria, Australia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia

References

Explore related publications, articles, or registry entries linked to this study.

Tiruvoipati R, Reddy MP, Paul E, Gupta S, Subramaniam A, Zhang D, Haji K. A comparison of conventional high-flow nasal cannula vs the duet high-flow nasal cannula in extubated patients: a randomized crossover trial. Eur J Med Res. 2025 Mar 26;30(1):205. doi: 10.1186/s40001-025-02447-0.

Reference Type DERIVED
PMID: 40140950 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

87400

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.